Highest-materiality recent filing
Instil Bio discontinues AXN-2510, pivots to acquisitions; cash $76.3M
Discontinued clinical development of AXN-2510; terminated license with ImmuneOnco.
Instil Bio subsidiary terminates license deal with ImmuneOnco for AXN-2510 and AXN-27M
Axion Bio (Instil Bio subsidiary) terminated License and Collaboration Agreement with ImmuneOnco effective Jan 5, 2026.
Instil Bio reports Q3 net loss $2.01/share; first patient dosed in Phase 1 trial of AXN-2510
Cash position $83.4M as of Sept 30, 2025, down from $115.1M at Dec 31, 2024; expects runway beyond 2026.
ImmuneOnco reports 62% partial response rate in Phase 2 NSCLC trial of IMM2510 + chemo
As of July 1, 2025, 33 patients dosed at 10 mg/kg; 21 efficacy-evaluable patients.
Phase 2 trial of IMM2510 + chemo in first-line NSCLC in China to complete enrollment of ~60 patients by Q3 2025.
Instil Bio Q1 net loss $4.32/share; restructuring charges $16.1M; cash $111.8M
Net loss per share $4.32 (GAAP) vs $3.74 YoY; non-GAAP $1.32 vs $2.39.
Instil Bio enters $100M at-the-market stock offering with Jefferies
Sales agreement with Jefferies LLC allows ATM sales of up to $100M in common stock.
Instil Bio Q4 net loss $1.82/sh; cash $115.1M; AXN-2510 NSCLC data expected 1H2025
GAAP net loss per share $1.82 in Q4, full year $11.39; non-GAAP $1.08 and $7.59 respectively.
ImmuneOnco doses first patient in Instil's IMM2510 Phase 1b/2 NSCLC trial; data in 2H 2025
ImmuneOnco dosed first patient in combined-chemotherapy trial for advanced NSCLC in China.
Instil Bio Q3 net loss $3.54/sh; cash $122.9M; licensed PD-L1xVEGF bispecific SYN-2510
Licensed SYN-2510 (PD-L1xVEGF bispecific) and SYN-27M (CTLA-4 antibody) from ImmuneOnco for global ex-China rights.
Instil Bio to close remaining UK operations, cut workforce, incur up to $5.5M in restructuring costs
Board approved restructuring plan to close Manchester, UK operations and eliminate remaining UK workforce.
Instil Bio Q2 net loss $2.29/share; in-licenses two assets, leases facility to AstraZeneca
Net loss per share $2.29 (GAAP), non-GAAP $1.57 for Q2 2024; improved from $2.87 and $2.03 in Q2 2023.
Instil Bio licenses bispecific and CTLA-4 antibodies from ImmuneOnco in deal up to $2.15B
SynBioTx (Instil subsidiary) gains exclusive license to IMM2510 (PD-L1/VEGF) and IMM27M (CTLA-4) outside Greater China.
Instil Bio reports Q4 net loss $1.99/share; ends ITIL-306 trial, closes UK facility
Cash and investments of $175.0M as of Dec 31, 2023, down from $260.9M a year earlier; runway expected beyond 2026.
Board approved closure of UK manufacturing and clinical operations; UK workforce reduced by ~61%.
Instil Bio Q3 net loss $67.4M; restructuring charges $46.3M; cash runway beyond 2026
Net loss $67.4M ($0.52 per share) vs $56.2M ($0.43) in Q3 2022.
Instil Bio Q2 2023 net loss $18.7M; cash $202.9M, ITIL-306 trial start 2H 2023
Net loss of $18.7M ($0.14/share) vs. $59.0M loss in Q2 2022; R&D expenses down to $8.5M from $41.5M.
Instil Bio preclinical data show FRα-CoStAR enhances TIL activity; clinical restart H2 2023
Oral presentation at BSGCT conference on ITIL-306 preclinical data.
Instil Bio Q1 net loss $57.1M; cash $223.9M; ITIL-306 phase 1 expected in 2H 2023
Net loss of $57.1M ($0.44 per share) vs $54.1M ($0.42) in Q1 2022; restructuring charges of $24.6M.
Instil Bio reports 2022 net loss of $223M; cash runway beyond 2026; ITIL-306 phase 1 in 2H 2023
Cash & marketable securities $260.9M (Dec 31, 2022) vs $454.1M in 2021; cash runway beyond 2026 with <$10M quarterly burn from 2H 2023.
Instil Bio confirms no cash or securities held at Silicon Valley Bank
Instil Bio holds no cash deposits or securities at Silicon Valley Bank.
Instil Bio cuts US headcount to ~15, consolidates operations to UK, expects cash runway beyond 2026
Will extend reduction-in-force to ~15 US employees; transition ITIL-306 manufacturing and trial to Manchester, UK.
Instil Bio receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq notice on Jan 24, 2023 for non-compliance with minimum bid price rule (bid < $1 for 30 consecutive days).
Instil Bio resumes Phase 1 trial of ITIL-306; initial data expected in 2023
Phase 1 trial of ITIL-306 (CoStAR-TIL) for NSCLC, ovarian, and renal cancer re-opened after voluntary pause.
Instil Bio discontinues ITIL-168, cuts 60% of U.S. workforce, COO departs
Discontinuing ITIL-168 (unmodified TIL) programs; prioritizing CoStAR-TIL platform (ITIL-306) in Phase 1 for NSCLC, ovarian, RCC.
Instil Bio Q3 net loss $56.2M; DELTA-1 trial paused; CMO resigns
Q3 net loss $56.2M ($0.43/share); cash & securities $303.3M at Sept 30, down from $454.1M at Dec 31, 2021.
Instil Bio voluntarily pauses enrollment in three clinical trials over manufacturing issues
Voluntary pause in DELTA-1 Phase 2 trial of ITIL-168 for advanced melanoma due to decreased manufacturing success rate causing inability to dose some patients.
Instil Bio doses first patient with ITIL-306 CoStAR-TIL in Phase 1 NSCLC trial
First patient dosed in Phase 1 study of ITIL-306, a CoStAR-engineered TIL therapy targeting FRα in non-small cell lung cancer.
Instil Bio appoints Tim Moore as COO, CTO Vijay Chiruvolu resigns
Tim Moore appointed COO effective Sept 6, 2022; previously President/COO at PACT Pharma and EVP at Kite.
Timothy Moore, the Company’s Chief Operating Officer, will separate from the Company, effective December 8, 2022.
On September 6, 2022 (the “Effective Date”), the board of directors (the “Board”) of Instil Bio, Inc. (the “Company”) appointed Timothy L. Moore as Chief Operating Officer of the Company.
On December 17, 2021, Nimish Shah resigned, with immediate effect, from his role as a member of the board of directors (the “Board”) of Instil Bio, Inc. (the “Company”) and as a member of the Board’s audit committee (the “Audit Committee”).
Max materiality 0.85 · Median 0.60 · Most common event other_material